Background: People living with lupus may experience poor access to primary care and delayed specialty care.
Purpose: To identify characteristics that lead to increased odds of poor access to primary care for minorities hospitalized with lupus.
Methods: Cross-sectional design with 2011-2012 hospitalization data from South Carolina, North Carolina, and Florida. We used ICD-9 codes to identify lupus hospitalizations. Ambulatory care sensitive conditions were used to identify preventable lupus hospitalizations and measure access to primary care. Logistic regression was used to estimate the odds ratio for the association between predictors and having poor access to primary care. Sensitivity analysis excluded patients aged >65 years.
Results: There were 23,154 total lupus hospitalizations, and 2,094 (9.04%) were preventable. An adjusted model showed minorities aged ≥65 years (OR 2.501, CI 1.501, 4.169), minorities aged 40-64 years (OR 2.248, CI: 1.394, 3.627), minorities with Medicare insurance (OR 1.669, CI:1.353,2.059) and minorities with Medicaid (OR 1.662,CI:1.321, 2.092) had the highest odds for a preventable lupus hospitalization. Minorities with Medicare had significantly higher odds for ≥3 hospital days (OR 1.275, CI: 1.149, 1.415). Whites with Medicare (OR 1.291, CI: 1.164, 1.432) had the highest odds for ≥3 days.
Conclusions: Our data show that middle-aged minorities living with lupus and on public health insurance have a higher likelihood of poor access to primary care. Health care workers and policymakers should develop plans to identify patients, explore issues affecting access, and place patients with a community health worker or social worker to promote better access to primary care.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7518530 | PMC |
http://dx.doi.org/10.18865/ed.30.4.611 | DOI Listing |
J Am Med Inform Assoc
January 2025
Department of Health Policy, Stanford School of Medicine, Stanford, CA 94305, United States.
Objectives: The inclusion of social drivers of health (SDOH) into predictive algorithms of health outcomes has potential for improving algorithm interpretation, performance, generalizability, and transportability. However, there are limitations in the availability, understanding, and quality of SDOH variables, as well as a lack of guidance on how to incorporate them into algorithms when appropriate to do so. As such, few published algorithms include SDOH, and there is substantial methodological variability among those that do.
View Article and Find Full Text PDFJ Med Internet Res
January 2025
Biomedical Informatics & Data Science Section, The Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Background: Mobile devices offer an emerging opportunity for research participants to contribute person-generated health data (PGHD). There is little guidance, however, on how to best report findings from studies leveraging those data. Thus, there is a need to characterize current reporting practices so as to better understand the potential implications for producing reproducible results.
View Article and Find Full Text PDFDrugs Aging
January 2025
Center for Clinical Management Research, VA Ann Arbor Healthcare System, NCRC 016-308E, 2800 Plymouth Rd, Ann Arbor, MI, 48109, USA.
Background: Central nervous system (CNS)-active polypharmacy (defined as concurrent exposure to three or more antidepressant, antipsychotic, antiseizure, benzodiazepine, opioid, or nonbenzodiazepine benzodiazepine receptor agonists) is associated with significant potential harms in persons living with dementia (PLWD).We conducted a pilot trial to assess a patient nudge intervention's implementation feasibility and preliminary effectiveness to prompt deprescribing conversations between PLWD experiencing CNS-active polypharmacy and their primary care clinicians ("clinicians").
Methods: We used the electronic health record to identify PLWD prescribed CNS-active polypharmacy in primary care clinics from two health systems.
Cureus
January 2025
Critical Care Medicine, Rashid Hospital, Dubai Academic Health Corporation, Dubai, ARE.
Aim We aimed to determine the incidence of thrombotic complications and outcomes of critically ill COVID-19 patients admitted to the intensive care unit (ICU) and evaluate the association between combined antithrombotic therapy and mortality in ICU patients admitted for COVID-19 pneumonia. Methods We retrospectively collected data of adult critically ill patients with COVID-19 admitted to the ICU in a major hospital in Dubai during the COVID-19 pandemic. The primary outcome was in-hospital mortality.
View Article and Find Full Text PDFTransl Lung Cancer Res
December 2024
Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.
Background: Dabrafenib plus trametinib (Dab + Tram) is an approved targeted therapy in patients with mutated metastatic non-small cell lung cancer (NSCLC). Here, we report the efficacy, safety, and quality of life (QoL) results of Dab + Tram treatment in Chinese patients with mutation-positive metastatic NSCLC.
Methods: This is a single-arm, open-label, multicentre, phase II study (NCT04452877).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!